What is the hang time for a 3‑in‑1 total parenteral nutrition (TPN) admixture?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hang Time for 3-in-1 TPN Solutions

The hang time for 3-in-1 (all-in-one) TPN admixtures should not exceed 24 hours from the time of hanging, with the giving set changed upon each new dosing. 1

Standard Hang Time Recommendations

  • The American Society for Parenteral and Enteral Nutrition establishes a maximum 24-hour hang time for home parenteral nutrition admixtures, which applies to all-in-one formulations containing lipids, amino acids, and dextrose. 1

  • This 24-hour limit is critical because lipid peroxidation occurs within 24 hours after compounding, making this the primary limiting factor for stability of 3-in-1 admixtures. 2

  • Vitamins degrade at different rates after compounding, with fat-soluble vitamins showing significant degradation beyond 24 hours at infusion temperature (37°C), further supporting the 24-hour hang time limit. 3

Storage vs. Hang Time Distinction

It's essential to distinguish between storage stability and hang time:

  • 3-in-1 admixtures supplemented with vitamins and trace elements can be stored refrigerated (2-8°C) for up to 7 days when protected from light. 4

  • Once removed from refrigeration and hung for infusion at room temperature, the 24-hour clock begins, regardless of how long the bag was previously stored. 1, 3

  • At room temperature (25°C) with light exposure, supplemented 3-in-1 PN remains stable for only 48 hours maximum, but the conservative 24-hour hang time recommendation accounts for infusion at body temperature (37°C). 4

Key Stability Factors

The 24-hour limit is driven by multiple chemical and physical processes:

  • Lipid particle size remains stable, with no clinically significant coalescence occurring during the 24-hour infusion period at room temperature. 5, 6

  • Chemical stability, particularly vitamin degradation and lipid peroxidation, is the limiting factor rather than physical emulsion breakdown. 2

  • Alpha-tocopherol (vitamin E) shows approximately 24% loss within 24 hours, and other vitamins interact and degrade at varying rates. 3, 2

Critical Safety Considerations

  • Cold chain maintenance is mandatory from compounding through transport to the point of administration, with bags stored at 4°C until immediately before use. 7

  • The giving set must be changed with each new bag to prevent bacterial contamination and maintain sterility. 1

  • Continuous agitation should be avoided, as it may actually hasten lipid breakdown and cause visible oil layer formation by 72 hours. 5

  • Filtration during delivery does not extend hang time but may be used for additional safety without affecting lipid particle stability. 5

Related Questions

What is the recommended management of symptomatic bradycardia in a hemodynamically stable patient?
What acute diagnoses, immediate work‑up, and initial management should be considered for a 62‑year‑old man with poorly controlled type‑2 diabetes (HbA1c 12 %), hypertension, remote right‑hemispheric ischemic stroke, one‑week altered sleep and behavior and one‑day difficulty walking, normal renal and liver function, mildly elevated alkaline phosphatase, low‑normal albumin, slightly raised ESR, no papilledema, CT showing chronic encephalomalacia and age‑related atrophy, and ultrasound showing cholelithiasis, mildly increased bilateral renal cortical echogenicity and right hydronephrosis?
A 63‑year‑old man with type 2 diabetes mellitus, hypertension and a remote right‑hemispheric ischemic stroke presents with one week of altered sleep and behavior and one day of new‑onset gait difficulty; laboratory studies show normal renal and liver function tests, mildly elevated alkaline phosphatase, borderline low albumin, modestly raised erythrocyte sedimentation rate, hemoglobin 13.1 g/dL, leukocyte count 8.9 ×10⁹/L, platelet count 369 ×10⁹/L; non‑contrast CT of the head reveals chronic encephalomalacia with gliosis in the right cerebral hemisphere and age‑related cerebral atrophy; abdominal ultrasound shows cholelithiasis, bilateral mild renal cortical echogenicity and a small right hydronephrosis; ophthalmology evaluation shows no papilledema. What are the likely differential diagnoses and immediate management steps?
What scoring system should be used to risk‑stratify a patient presenting with an acute upper gastrointestinal bleed?
What is the recommended management of an acutely agitated patient?
Why can tonsillar inflammation, hypertrophy, or tonsillectomy cause abdominal pain in children?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.